T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
PACCAR
PCAR
$68.8B
| $249M | 0.03% |
2,275,921
+1,286,056
| +130% | +$132M |
|
402
Alcon
ALC
$35.5B
| $248M | 0.03% |
3,151,749
-7,103,801
| -69% | -$547M |
|
403
Alibaba
BABA
$293B
| $247M | 0.03% |
1,688,109
+1,208,219
| +252% | +$197M |
|
|
SEM
404
DELISTED
Select Medical
SEM
| $247M | 0.03% |
16,606,269
+684,695
| +4% | +$9.68M |
|
405
Ovintiv
OVV
$17.2B
| $245M | 0.03% |
6,257,804
-56,976
| -0.9% | -$2.21M |
|
406
Perrigo
PRGO
$1.78B
| $245M | 0.03% |
17,574,227
+653,925
| +4% | +$10.9M |
|
407
Waste Management
WM
$89.6B
| $244M | 0.03% |
1,108,418
+44,306
| +4% | +$9.44M |
|
408
Cemex
CX
$16B
| $243M | 0.03% |
21,191,754
+2,182,666
| +11% | +$22.6M |
|
409
Crinetics Pharmaceuticals
CRNX
$8.96B
| $243M | 0.03% |
5,224,387
-81,861
| -2% | -$3.64M |
|
410
Atmus Filtration Technologies
ATMU
$4.06B
| $243M | 0.03% |
4,677,884
+596,553
| +15% | +$28.9M |
|
411
Columbia Banking Systems
COLB
$9.18B
| $242M | 0.03% |
8,666,769
+5,063,212
| +141% | +$137M |
|
412
Avery Dennison
AVY
$13.6B
| $240M | 0.03% |
1,322,221
+74,063
| +6% | +$12.8M |
|
413
Xylem
XYL
$28.1B
| $240M | 0.03% |
1,765,321
-754,644
| -30% | -$109M |
|
414
Bio-Techne
TECH
$11.2B
| $240M | 0.03% |
4,075,194
+725,050
| +22% | +$44.1M |
|
415
Yum! Brands
YUM
$41.2B
| $238M | 0.03% |
1,573,753
-44,846
| -3% | -$6.64M |
|
416
Warrior Met Coal
HCC
$4.98B
| $238M | 0.03% |
2,700,028
-11,201
| -0.4% | -$842K |
|
|
CCC
417
CCC Intelligent Solutions
CCC
$4.19B
| $237M | 0.03% |
29,825,900
-419,789
| -1% | -$3.41M |
|
418
Ionis Pharmaceuticals
IONS
$9.28B
| $236M | 0.03% |
2,987,840
+258,155
| +9% | +$19.4M |
|
|
DOCU
419
DocuSign
DOCU
$12.2B
| $236M | 0.03% |
3,453,513
-446,296
| -11% | -$30.9M |
|
420
SPX Corp
SPXC
$10.6B
| $235M | 0.03% |
1,176,481
+84,117
| +8% | +$17.2M |
|
421
Live Nation Entertainment
LYV
$43.3B
| $233M | 0.03% |
1,631,740
-276,148
| -14% | -$39.7M |
|
422
The Ensign Group
ENSG
$10.6B
| $232M | 0.03% |
1,332,505
+118,110
| +10% | +$21.2M |
|
423
Lincoln National
LNC
$8.67B
| $232M | 0.03% |
5,208,356
+3,975
| +0.1% | +$166K |
|
424
Praxis Precision Medicines
PRAX
$10.3B
| $232M | 0.03% |
785,987
-217,503
| -22% | -$40.5M |
|
425
Global E Online
GLBE
$7.09B
| $231M | 0.02% |
5,872,341
+2,387,242
| +68% | +$88.6M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.